#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Genitourinary syndrome of menopause: hard to communicate, easy to treat


Authors: Tomáš Fait
Authors‘ workplace: Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha
Published in: Čas. Lék. čes. 2019; 158: 101-106
Category: Review Article

Overview

About 40 % of woman suffer from vulvovaginal atrophy after menopausal transition. It is very important to put question on this problem, because about 70 % of them are not able to start discussion on it. Regarding treatment, vaginal low doses estriol and estradiol are drugs of first choice with high efficacy and safety.

Keywords:

genitourinary syndrome of menopause – vulvovaginal atrophy – vaginal application – estriol – estradiol – ospemifene – prasteron


Sources
  1. Portman DJ, Gass MLS. Genitourinary syndrome of menopause. Climacteric 2014; 1: 557–556.

  2. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. AJOG 1989; 16: 176–181.

  3. Versi E, Cardozo L. Urethral vascular pulsation. Proc Int Cont Soc 198: 503–594.

  4. Ulmsten U, Ekman G, Gierrz G, Malmstrom A. Different biochemical composition of connective tissue in continents and stress incontinent women. Acta Obstet Gynecol Scand 1987; 6: 147–152.

  5. Rud T. The effect of estrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gyn Scand 1980; 5: 265–270.

  6. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994; 8: 12–18.

  7. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012; 15: 267–274.

  8. Cardozo L, Bachmann G, Mc Clish D et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women. Obstet Gynecol 1998; 9: 722–727.

  9. Nappi RE, Liekens G, Brandenburg U. Attitudes, perceptions and knowledges about vagina. the International Vagina Dialogue Survey. Contraception 2006; 7: 493–500.

  10. Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause. Results from an international survey on vaginal atrophy. Maturitas 2010; 6: 233–238.

  11. Nappi RE, Kokot-Kierepa M. Vaginal Health. Insights Views & Attitudes (VIVA) – results from an international survey. Climacteric 2012; 1: 36–44.

  12. Nappi RE, Mattsson LA, Lachowsky M et al. The CLOSER survey. Impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas 2013; 75: 373–379.

  13. Erekson EA, Yip SO, Wedderburn TS et al. The VSQ: a questionnaire to measure vulvovaginal symptoms in postmenopausal women. Menopause 2013; 20: 973–979.

  14. Huang AJ, Gregorich SE, Kuppermann M et al. Day-to-day impact of vaginal aging questionnaire. Menopause 2014; 2: 144–154.

  15. The North American Menopause Society. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017; 2: 728–753.

  16. Cardozo L. A systematic review of estrogens for recurrent urinary tract infections. Int Urogynecol J 1999; 10(Suppl. 1), S32.

  17. Rioux JE. Demlin C, Gelfand EE et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156–161.

  18. Simon J, Nachtigall L, Gut R et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008; 112: 1053–1060.

  19. Ulrich LSG, Naessen T, Elia D et al. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010; 1: 228–237.

  20. Simon J, Nachtigall L, Ulrich LG et al. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116: 876–883.

  21. Labrie F, Martel C, Bélanger A, Pelletier G. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. J Steroid Biochem Mol Biol 2017; 16: 9–18.

  22. Labrie F, Derogatis L, Archer DF et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med 2015; 12: 2401–2412.

  23. DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene. a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 2014; 9: 82–93.

  24. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-estrogen selective estrogen receptor regulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy. Maturitas 2014; 7: 91–98.

  25. Constatine G, Graham S, Portman DJ. et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014; 1: 1–7.

  26. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women. Menopause 2010; 1: 480–486.

  27. Portman DJ, Bachman GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulva rand vaginal atrophy. Menopause 2013; 2: 623–30.

  28. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 2: 418–27.

  29. Behnia-Willison F, Sarraf S, Miller J et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol 2017; 21: 39–44.

  30. Perino A, Cucinelle G, Gugliotta G et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients. Preliminary results. Eur Rev Med Pharm Sci 2016; 20; 1: 2491–2497.

  31. Salvatore S, Leone RMU, Athanasiou S et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue. an ex vivo study. Menopause 2015; 22: 845–849.

  32. Siliquini GP, Tuninetti V, Bournous VE et al. Fractional CO2 laser therapy. a new challenge for vulvovaginal atrophy in postmenopausal women. Climacteric 2017;20: 379–384.

  33. Eriksen B. A randomized, open, parallel group-study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infection in postmenopausal women. Am J Obstet Gynecol 1999; 180: 1072–1079.

  34. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New Engl J Med 1993; 32: 753–756.

  35. Kirkengen AL, Andersen P, Gjersoe E et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scan J Prim Health Care 1992; 1: 139–142.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management

Article was published in

Journal of Czech Physicians

Issue 3-4

2019 Issue 3-4

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#